Elevated PCSK9 occurs in a Brown Norway rat microbead model of glaucoma

被引：0
|
作者：
Mysona, Barbara A. [1 ,2 ]
Zhao, Jing [1 ,2 ]
De Greef, Oceane [3 ]
Bollinger, Kathryn E. [2 ,4 ]
机构：
[1] Augusta Univ, Cellular Biol & Anat, Augusta, GA USA
[2] James & Jean Culver Vis Discovery Inst, Augusta, GA USA
[3] Augusta Univ, STAR Program, Augusta, GA USA
[4] Augusta Univ Med Coll Georgia, Ophthalmol, Augusta, GA USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2024年 / 65卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
1678
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Automated analysis of axons and glia in a Brown Norway rat model of glaucoma, comparison of QuPath to AxonJ
    Mysona, Barbara A.
    Segar, Sharmila
    Zhao, Jing
    Bollinger, Kathryn E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [22] COST EFFECTIVENESS OF AN OUTCOME BASED REIMBURSEMENT MODEL OF PCSK9 INHIBITORS
    Oren, Ohad
    Oren, Michal
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1753 - 1753
  • [23] Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes
    Rohrbach, Susanne
    Li, Ling
    Novoyatleva, Tatyana
    Niemann, Bernd
    Knapp, Fabienne
    Molenda, Nicole
    Schulz, Rainer
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [24] Effects of immunization against PCSK9 in an experimental model of breast cancer
    Momtazi-Borojeni, Amir Abbas
    Nik, Maryam Ebrahimi
    Jaafari, Mahmoud Reza
    Banach, Maciej
    Sahebkar, Amirhossein
    ARCHIVES OF MEDICAL SCIENCE, 2019, 15 (03) : 570 - 579
  • [25] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial
    Katsiki, Niki
    Athyros, Vasilios G.
    Mikhailidis, Dimitri P.
    Mantzoros, Christos
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 74 : 43 - 46
  • [26] PCSK9 IN ATHEROSCLEROTIC INFLAMMATION OF LUPUS PATIENTS AND MURINE MODEL OF LUPUS WITH ATHEROSCLEROSIS
    Fang, Chenglong
    Luo, Tingting
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 230 - 231
  • [27] ANGPTL3 INTERACTS AND INHIBITS PCSK9 IN AN IN VITRO CELLULAR MODEL
    Bini, Simone
    D'Erasmo, Laura
    Minicocci, Ilenia
    Di Costanzo, Alessia
    Tramontano, Daniele
    Covino, Stella
    Arca, Marcello
    Pecce, Valeria
    ATHEROSCLEROSIS, 2024, 395
  • [28] Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study
    Kheirkhah, Azin
    Lamina, Claudia
    Rantner, Barbara
    Kollerits, Barbara
    Stadler, Marietta
    Pohlhammer, Johannes
    Klein-Weigel, Peter
    Fraedrich, Gustav
    Kronenberg, Florian
    ATHEROSCLEROSIS, 2021, 316 : 41 - 47
  • [29] Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
    Sabatine, Marc S.
    Giugliano, Robert P.
    Keech, Anthony
    Honarpour, Narimon
    Wang, Huei
    Liu, Thomas
    Wasserman, Scott M.
    Scott, Robert
    Sever, Peter S.
    Pedersen, Terje R.
    AMERICAN HEART JOURNAL, 2016, 173 : 94 - 101
  • [30] Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies
    Almontashiri, Naif A. M.
    Vilmundarson, Ragnar O.
    Ghasemzadeh, Nima
    Dandona, Sonny
    Roberts, Robert
    Quyyumi, Arshed A.
    Chen, Hsiao-Huei
    Stewart, Alexandre F. R.
    PLOS ONE, 2014, 9 (09):
12345